Global Schizophrenia Drugs Market: Size, Trends & Forecast (2018-2022)
Scope of the Report
The report entitled “Global Schizophrenia Drugs Market: Size, Trends & Forecast (2018-2022)”, provides an in-depth analysis of the global biologics market with description of market sizing and growth. The analysis includes market by value, and market by region. A detailed product analysis of schizophrenia drugs is also provided in the report.
The report includes a brief regional/country analysis of the US, European Union and Japan with their actual and forecasted market size. The U.S. has the largest stake in the global schizophrenia market over the years and is expected to maintain its position in the upcoming years also. Among the Asian countries, Japan is the largest market and has the potential to grow steadily over the forecasted period.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global schizophrenia drugs market has also been forecasted for the years 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
The global schizophrenia drugs market is dominated by major players. Eli Lilly & Company, Otsuka Holdings Co., Ltd., Johnson & Johnson, and Alkermes plc are some of the key players operating in the global market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the respective companies are provided.
Company Coverage
Schizophrenia is considered as one of the severe mental disorder that hinders the person’s capacity to think clearly, decision-making, inability to handle emotions etc. It is highly complex in nature as it cannot be easily determined and considered as a long-term illness. Schizophrenia can affect in any phase of life but mostly found in person aged between 20-40 years.
The global schizophrenia drugs market has shown rising trends over the past few years and anticipations are made that the market would grow at a steady pace in the next four years i.e. 2018 to 2022, particularly due to increasing prevalence of schizophrenia globally. The global schizophrenia market is supported by various growth drivers such as increasing number of patients seeking treatment, rising healthcare expenditure, improvement in healthcare infrastructure etc.
Yet the market growth is restrained by some challenges like side-effects associated with drugs, major expiration of patented drugs, and social stigma of mental health conditions. In the coming years, the market would be primarily driven by technological advancements, new products launch, increasing utilization of long-acting injectable antipsychotics.
The report entitled “Global Schizophrenia Drugs Market: Size, Trends & Forecast (2018-2022)”, provides an in-depth analysis of the global biologics market with description of market sizing and growth. The analysis includes market by value, and market by region. A detailed product analysis of schizophrenia drugs is also provided in the report.
The report includes a brief regional/country analysis of the US, European Union and Japan with their actual and forecasted market size. The U.S. has the largest stake in the global schizophrenia market over the years and is expected to maintain its position in the upcoming years also. Among the Asian countries, Japan is the largest market and has the potential to grow steadily over the forecasted period.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global schizophrenia drugs market has also been forecasted for the years 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
The global schizophrenia drugs market is dominated by major players. Eli Lilly & Company, Otsuka Holdings Co., Ltd., Johnson & Johnson, and Alkermes plc are some of the key players operating in the global market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the respective companies are provided.
Company Coverage
- Eli Lilly & Company
- Otsuka Holdings Co., Ltd.
- Johnson & Johnson
- Alkermes plc
Schizophrenia is considered as one of the severe mental disorder that hinders the person’s capacity to think clearly, decision-making, inability to handle emotions etc. It is highly complex in nature as it cannot be easily determined and considered as a long-term illness. Schizophrenia can affect in any phase of life but mostly found in person aged between 20-40 years.
The global schizophrenia drugs market has shown rising trends over the past few years and anticipations are made that the market would grow at a steady pace in the next four years i.e. 2018 to 2022, particularly due to increasing prevalence of schizophrenia globally. The global schizophrenia market is supported by various growth drivers such as increasing number of patients seeking treatment, rising healthcare expenditure, improvement in healthcare infrastructure etc.
Yet the market growth is restrained by some challenges like side-effects associated with drugs, major expiration of patented drugs, and social stigma of mental health conditions. In the coming years, the market would be primarily driven by technological advancements, new products launch, increasing utilization of long-acting injectable antipsychotics.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Mental Disorder: An Overview
2.1.1 Types of Mental Disorders
2.2 Psychotic Disorder: An Overview
2.2.1 Psychotic Disorder: Definition
2.3 Schizophrenia: An Overview
2.3.1 Schizophrenia: Definition
2.3.2 Causes of Schizophrenia
2.3.3 Symptoms of Schizophrenia
2.3.4 Treatment of Schizophrenia
3. GLOBAL MARKET ANALYSIS
3.1 Global Schizophrenia Drugs Market Analysis
3.1.1 Global Schizophrenia Drugs Market by Value
3.1.2 Global Schizophrenia Drugs Market by Region
4. PRODUCT ANALYSIS
4.1 Global Schizophrenia Long-Acting Injectables Product Analysis
4.1.1 ABILIFY MAINTENA (Aripiprazole)
4.1.2 INVEGA SUSTENNA (Paliperidone Palmitate)
4.1.3 RISPERDAL CONSTA (Risperidone)
4.1.4 ZYPREXA RELPREV (Olanzapine)
4.1.5 ARISTADA ((Aripiprazole Lauroxil)
5. REGIONAL MARKET ANALYSIS
5.1 The U.S. Schizophrenia Drugs Market Analysis
5.1.1 The U.S. Schizophrenia Drugs Market by Value
5.2 European Union Schizophrenia Drugs Market Analysis
5.2.1 European Union Schizophrenia Drugs Market by Value
5.3 Japan Schizophrenia Drugs Market Analysis
5.3.1 Japan Schizophrenia Drugs Market by Value
6. MARKET DYNAMICS
6.1 Growth Drivers
6.1.1 Increasing Number of Patients Seeking Treatment
6.1.2 Growing Awareness of Mental Healthcare
6.1.3 Rising Healthcare Spending
6.1.4 Improvement in Healthcare Infrastructure
6.2 Challenges
6.2.1 Side-effects Associated with Drugs
6.2.2 Social Stigma of Mental Health Conditions
6.2.3 Major Expiration of Patented Drug
6.2.4 Achieving Treatment Adherence
6.3 Market Trends
6.3.1 New Products Launch
6.3.2 Increasing Utilization of Long-Acting Injectable Antipsychotics
6.3.3 Availability of Drugs with Novel Mechanism of Action (MoA)
7. COMPETITIVE LANDSCAPE
7.1 Global Schizophrenia Drugs Market Competitive Landscape
7.2 Global Schizophrenia Drugs Market by Players
8. COMPANY PROFILES
8.1 Eli Lilly & Company
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2 Otsuka Holdings Co., Ltd.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy
8.3 Johnson & Johnson
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy
8.4 Alkermes plc
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategy
2. INTRODUCTION
2.1 Mental Disorder: An Overview
2.1.1 Types of Mental Disorders
2.2 Psychotic Disorder: An Overview
2.2.1 Psychotic Disorder: Definition
2.3 Schizophrenia: An Overview
2.3.1 Schizophrenia: Definition
2.3.2 Causes of Schizophrenia
2.3.3 Symptoms of Schizophrenia
2.3.4 Treatment of Schizophrenia
3. GLOBAL MARKET ANALYSIS
3.1 Global Schizophrenia Drugs Market Analysis
3.1.1 Global Schizophrenia Drugs Market by Value
3.1.2 Global Schizophrenia Drugs Market by Region
4. PRODUCT ANALYSIS
4.1 Global Schizophrenia Long-Acting Injectables Product Analysis
4.1.1 ABILIFY MAINTENA (Aripiprazole)
4.1.2 INVEGA SUSTENNA (Paliperidone Palmitate)
4.1.3 RISPERDAL CONSTA (Risperidone)
4.1.4 ZYPREXA RELPREV (Olanzapine)
4.1.5 ARISTADA ((Aripiprazole Lauroxil)
5. REGIONAL MARKET ANALYSIS
5.1 The U.S. Schizophrenia Drugs Market Analysis
5.1.1 The U.S. Schizophrenia Drugs Market by Value
5.2 European Union Schizophrenia Drugs Market Analysis
5.2.1 European Union Schizophrenia Drugs Market by Value
5.3 Japan Schizophrenia Drugs Market Analysis
5.3.1 Japan Schizophrenia Drugs Market by Value
6. MARKET DYNAMICS
6.1 Growth Drivers
6.1.1 Increasing Number of Patients Seeking Treatment
6.1.2 Growing Awareness of Mental Healthcare
6.1.3 Rising Healthcare Spending
6.1.4 Improvement in Healthcare Infrastructure
6.2 Challenges
6.2.1 Side-effects Associated with Drugs
6.2.2 Social Stigma of Mental Health Conditions
6.2.3 Major Expiration of Patented Drug
6.2.4 Achieving Treatment Adherence
6.3 Market Trends
6.3.1 New Products Launch
6.3.2 Increasing Utilization of Long-Acting Injectable Antipsychotics
6.3.3 Availability of Drugs with Novel Mechanism of Action (MoA)
7. COMPETITIVE LANDSCAPE
7.1 Global Schizophrenia Drugs Market Competitive Landscape
7.2 Global Schizophrenia Drugs Market by Players
8. COMPANY PROFILES
8.1 Eli Lilly & Company
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2 Otsuka Holdings Co., Ltd.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy
8.3 Johnson & Johnson
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy
8.4 Alkermes plc
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategy
LIST OF FIGURES
Figure 1: Types of Mental Disorders
Figure 2: Causes of Schizophrenia
Figure 3: Symptoms of Schizophrenia
Figure 4: Global Schizophrenia Drugs Market by Value; 2012-2017 (US$ Billion)
Figure 5: Global Schizophrenia Drugs Market by Value; 2018-2022E (US$ Billion)
Figure 6: Global Schizophrenia Drugs Market by Region; 2017 & 2022
Figure 7: ABILIFY MAINTENA Global Sales; 2016-2017 (US$ Million)
Figure 8: INVEGA SUSTENNA Global Sales; 2015-2017 (US$ Billion)
Figure 9: RISPERDAL CONSTA Global Sales; 2015-2017 (US$ Million)
Figure 10: ZYPREXA RELPREV Global Sales; 2015-2017 (US$ Million)
Figure 11: The U.S. ARISTADA Sales; 2016-2018E (US$ Million)
Figure 12: The U.S. Schizophrenia Drugs Market by Value; 2012-2017 (US$ Billion)
Figure 13: The U.S. Schizophrenia Drugs Market by Value; 2018-2022E (US$ Billion)
Figure 14: European Union Schizophrenia Drugs Market by Value; 2012-2017 (US$ Billion)
Figure 15: European Union Schizophrenia Drugs Market by Value; 2018-2022E (US$ Billion)
Figure 16: Japan Schizophrenia Drugs Market by Value; 2012-2017 (US$ Billion)
Figure 17: Japan Schizophrenia Drugs Market by Value; 2018-2022E (US$ Billion)
Figure 18: Global Health Care Spending; 2015-2020 (US$ Trillion)
Figure 19: Global Schizophrenia Market Players by Drugs Sales; 2017 (US$ Million)
Figure 20: Eli Lily & Company Revenue; 2013-2017 (US$ Billion)
Figure 21: Eli Lily & Company Revenue by Segments; 2017
Figure 22: Eli Lily & Company Revenue by Geography; 2017
Figure 23: Otsuka Holdings Co., Ltd. Net Sales; 2013-2017 (US$ Billion)
Figure 24: Johnson & Johnson Net Sales; 2013-2017 (US$ Billion)
Figure 25: Johnson & Johnson Sales by Segments; 2017
Figure 26: Johnson & Johnson Sales by Geography; 2017
Figure 27: Alkermes plc Revenue; 2013-2017 (US$ Million)
Figure 28: Alkermes plc Revenue by Segments; 2017
Figure 29: Alkermes plc Revenue by Geography; 2017
Figure 1: Types of Mental Disorders
Figure 2: Causes of Schizophrenia
Figure 3: Symptoms of Schizophrenia
Figure 4: Global Schizophrenia Drugs Market by Value; 2012-2017 (US$ Billion)
Figure 5: Global Schizophrenia Drugs Market by Value; 2018-2022E (US$ Billion)
Figure 6: Global Schizophrenia Drugs Market by Region; 2017 & 2022
Figure 7: ABILIFY MAINTENA Global Sales; 2016-2017 (US$ Million)
Figure 8: INVEGA SUSTENNA Global Sales; 2015-2017 (US$ Billion)
Figure 9: RISPERDAL CONSTA Global Sales; 2015-2017 (US$ Million)
Figure 10: ZYPREXA RELPREV Global Sales; 2015-2017 (US$ Million)
Figure 11: The U.S. ARISTADA Sales; 2016-2018E (US$ Million)
Figure 12: The U.S. Schizophrenia Drugs Market by Value; 2012-2017 (US$ Billion)
Figure 13: The U.S. Schizophrenia Drugs Market by Value; 2018-2022E (US$ Billion)
Figure 14: European Union Schizophrenia Drugs Market by Value; 2012-2017 (US$ Billion)
Figure 15: European Union Schizophrenia Drugs Market by Value; 2018-2022E (US$ Billion)
Figure 16: Japan Schizophrenia Drugs Market by Value; 2012-2017 (US$ Billion)
Figure 17: Japan Schizophrenia Drugs Market by Value; 2018-2022E (US$ Billion)
Figure 18: Global Health Care Spending; 2015-2020 (US$ Trillion)
Figure 19: Global Schizophrenia Market Players by Drugs Sales; 2017 (US$ Million)
Figure 20: Eli Lily & Company Revenue; 2013-2017 (US$ Billion)
Figure 21: Eli Lily & Company Revenue by Segments; 2017
Figure 22: Eli Lily & Company Revenue by Geography; 2017
Figure 23: Otsuka Holdings Co., Ltd. Net Sales; 2013-2017 (US$ Billion)
Figure 24: Johnson & Johnson Net Sales; 2013-2017 (US$ Billion)
Figure 25: Johnson & Johnson Sales by Segments; 2017
Figure 26: Johnson & Johnson Sales by Geography; 2017
Figure 27: Alkermes plc Revenue; 2013-2017 (US$ Million)
Figure 28: Alkermes plc Revenue by Segments; 2017
Figure 29: Alkermes plc Revenue by Geography; 2017
LIST OF TABLES
Table 1: Promising Compounds in Clinical Development for the Treatment of Schizophrenia in Adults
Table 2: Global Schizophrenia Drugs Competitive Landscape by Products
Table 3: Otsuka Group - Pipeline Information
Table 4: Key Marketed Products for Schizophrenia
Table 5: Key Marketed Products
Table 6: Alkermes Development Pipeline Overview
Table 1: Promising Compounds in Clinical Development for the Treatment of Schizophrenia in Adults
Table 2: Global Schizophrenia Drugs Competitive Landscape by Products
Table 3: Otsuka Group - Pipeline Information
Table 4: Key Marketed Products for Schizophrenia
Table 5: Key Marketed Products
Table 6: Alkermes Development Pipeline Overview
